{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:07Z","timestamp":1790409247977,"version":"4.1.0"},"reference-count":121,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Treatment of multiple myeloma (MM) has evolved significantly over the past few decades. Up-front treatment options expanded from doublet regimens to triplets and now to quadruplets. Monoclonal antibodies have significantly contributed to this paradigm shift. Their incorporation into frontline regimens demonstrated improved survival outcomes irrespective of transplantation eligibility. Autologous hematopoietic stem-cell transplant (ASCT) remains standard in frontline consolidation therapy with recent expansion of eligibility, including older adults and patients with renal failure. The growing understanding of physiologic age and frailty, as well as improvements in supportive care, has made this possible. Bispecific T-cell engager (BiTE) antibodies are heralding a new age of treatment of MM with high response rates in patients with relapsed or refractory MM. With the impressive responses seen, these treatments are being studied in earlier lines of therapy and in combination with other therapies. With this rapidly evolving field of immunotherapy in MM, the goal of this review was to discuss the latest advances in MM treatment, focusing on up-front quadruplet therapy, the role of ASCT in the modern era, and the evolving role of BiTEs in up-front therapy.<\/jats:p>","DOI":"10.1200\/edbk-25-473316","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:05:50Z","timestamp":1748466350000},"source":"Crossref","is-referenced-by-count":4,"title":["Current and Future Directions of Immunotherapies in Multiple Myeloma"],"prefix":"10.1200","volume":"45","author":[{"given":"Eden M.D.","family":"Biltibo","sequence":"first","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malini","family":"Surapaneni","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaya","family":"Suvannasankha","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-5945","authenticated-orcid":true,"given":"Reena V.","family":"Jayani-Kosarzycki","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","volume-title":"Novel Drug Approvals at FDA","author":"US Food and Drug Administration","unstructured":"US Food and Drug Administration: Novel Drug Approvals at FDA. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160090040009"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014889"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003454"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.043372"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm178"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03581-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00282-1"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02266"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00428-9"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","unstructured":"Manier S Dimopoulos MA Leleu AP: Isatuximab plus bortezomib lenalidomide and dexamethasone (VRd) for newly diagnosed multiple myeloma (NDMM) transplant-ineligible patients: Frailty subgroup analysis of IMROZ. International Myeloma Society 21st Annual Meeting & Exposition Riocentro Rio de Janeiro Brazil 2024. p P426","DOI":"10.1016\/S2152-2650(24)02347-4"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203170"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90739-0"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198405243102104"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.5.1298.1298"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00693-3"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-297325"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.198"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124804"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172546"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.255"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.7561"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01097-9"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.09.012"},{"key":"e_1_3_3_45_2","unstructured":"Dotan E Walter LC Beechinor R et al: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Older Adult Oncology V.1.2025. National Comprehensive Cancer Network"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0918-6"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.028"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25797"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.404.404"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.27.27"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33003-4"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150476"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114083"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114138"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019531"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00738-0"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02567"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8506"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14101030"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.08.006"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178882"},{"key":"e_1_3_3_71_2","first-page":"875","volume-title":"KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation","author":"Usmani S","year":"2022","unstructured":"Usmani S, Patel K, Hari P, et al: KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. New Orleans, Louisiana, American Society of Hematology, 2022, pp 875-877"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162615"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.119.1.151"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00501"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/2515135518763280"},{"key":"e_1_3_3_78_2","volume-title":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma","author":"Administration FaD","unstructured":"Administration FaD: FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. FDA. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_3_79_2","unstructured":"Administration FaD: FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma"},{"key":"e_1_3_3_80_2","unstructured":"Administration FaD: FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01666-5"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01689-6"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.003"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00385-5"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025987"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199542"},{"key":"e_1_3_3_93_2","first-page":"e328","article-title":"Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of \u201cprogression-free survival 2\u201d as a clinical trial end-point","volume":"100","author":"Dimopoulos MA","year":"2015","unstructured":"Dimopoulos MA, Petrucci MT, Fo\u00e0 R, et al: Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of \u201cprogression-free survival 2\u201d as a clinical trial end-point. Haematologica 100:e328-e330, 2015","journal-title":"Haematologica"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-24-0292"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01664-1"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970532.16622.f0"},{"key":"e_1_3_3_101_2","volume-title":"Early Treatment with Bispecific T-Cell Redirectors (Teclistamab or Talquetamab) + Daratumumab in Newly Diagnosed High-Risk Multiple Myeloma: An Open-Label, Phase 2, Pilot Study (GEM-TECTAL)","author":"Rodriguez-Ortero P","year":"2023","unstructured":"Rodriguez-Ortero P, Mateos M-V, Palacios JJL, et al: Early Treatment with Bispecific T-Cell Redirectors (Teclistamab or Talquetamab) + Daratumumab in Newly Diagnosed High-Risk Multiple Myeloma: An Open-Label, Phase 2, Pilot Study (GEM-TECTAL). International Myeloma Society 20th Annual Meeting and Exposition. Athens, Greece, 2023"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206003"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203364"},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205608"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200210"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8066"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180458"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205989"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180660"},{"key":"e_1_3_3_111_2","volume-title":"Study of Teclistamab in Combination in Elderly Patients with Multiple Myeloma (IFM2021-01)","unstructured":"Study of Teclistamab in Combination in Elderly Patients with Multiple Myeloma (IFM2021-01). https:\/\/clinicaltrials.gov\/study\/NCT05572229?term=IFM2021-01&rank=1"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000936248.01150.e8"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7506"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8065"},{"key":"e_1_3_3_116_2","volume-title":"Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients","author":"ClinicalTrials.gov","unstructured":"ClinicalTrials.gov: Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients. https:\/\/clinicaltrials.gov\/study\/NCT06758375?term=NCT06758375&rank=1"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177735"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08233-0"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.971"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:06:09Z","timestamp":1748466369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473316"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473316","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473316"}}